Evidence Hub

Causal relationship between gut microbiota and hepatocellular carcinoma: a two-sample Mendelian randomization and case–control study

Liu Yang, Wei Wei, Yuekui Wang, Wen-Tao Kuai, Liang Xu

Discover Oncology, 2025

29 participants · 4 citations

Abstract

Accumulating evidence from both observational studies and clinical trials has established a connection between the gut microbiome and hepatocellular carcinoma (HCC). Nevertheless, the causal relationship between gut microbes and hepatocellular carcinoma remains ambiguous. The principal study method employed was Mendelian randomization (MR). The exposure group included 7738 samples from the MiBioGen Consortium Gut Microbiota Genome-Wide Association Study (GWAS), whereas the outcome group included 8,885,115 single nucleotide polymorphisms (SNPs) from the IEU OpenGWAS project database of hepatocellular carcinoma (HCC). Utilizing the MR-Egger regression, weighted median (WME), and weighted mode (WM) as supplemental methods for inverse variance weighting (IVW), the main basis was IVW. Additional sensitivity, pleiotropy, and heterogeneity tests were performed. To confirm the MR results, sequencing data from a case–control study were used. We enrolled 29 patients with HBV-HCC who were hospitalized at Tianjin Second People's Hospital between October 2022 and August 2023, and chose 21 healthy employees as controls. IVW analysis showed that gut Clostridia (OR = 0.554, 95%CI: 0.361–0.850, p = 0.007), Clostridiales (OR = 0.554, 95%CI: 0.361–0.850, p = 0.007), and Dorea (OR = 0.679, 95%CI: 0.479–0.964, p = 0.030) were protective factors against HCC. Gut Desulfovibrio piger (OR = 1.304, 95%CI: 1.080–1.499, p = 0.004), Bacteroides ovatus (OR = 1.304, 95%CI: 1.046–1.626, p = 0.018),…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free